Core Viewpoint - Corvus Pharmaceuticals, Inc. (CRVS) is experiencing significant stock price growth due to positive clinical trial results for its lead candidate, soquelitinib, and has a new price target set by Mizuho Securities indicating further potential upside [1][6]. Company Overview - Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company based in South San Francisco, focusing on innovative therapies for immune-related diseases [1]. Stock Performance - CRVS stock has surged by 209% over the past month following positive Phase I study results for soquelitinib, which showed a 72% reduction in the Eczema Area and Severity Index (EASI) [2][3]. - The current trading price of CRVS is $20.54, reflecting a 6.97% decrease today, with a market capitalization of approximately $1.53 billion [5]. Clinical Trial Results - The Phase I study for soquelitinib was a blinded, placebo-controlled trial involving patients who had previously undergone systemic therapy, confirming its potential as a "first-in-class" selective ITK inhibitor [4]. Financial Developments - Corvus Pharmaceuticals successfully closed an upsized public offering, raising approximately $201 million to support working capital, capital expenditures, and research and development, particularly for its Phase 3 T cell lymphoma program [3][6].

Key Takeaways CRVS shares jumped 208.8% in a month following positive cohort 4 results from a phase I eczema study.Corvus Pharmaceuticals reported deeper and more durable responses with eight-week dosing versus prior cohorts.CRVS said cohort 4 patients saw a 72% EASI reduction at day 56, with no disease flares or serious events.Shares of Corvus Pharmaceuticals (CRVS) have skyrocketed 208.8% in a month. The massive stock price rally was observed after the company announced positive results from cohort 4 of a ...

We recently published 10 Stocks With Effortless Double-, Triple-Digit Gains. Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) was one of the top performers last week. Corvus Pharmaceuticals soared by 211.8 percent week-on-week to hit a new all-time high, as investors cheered the strong results of its clinical trial testing the efficacy of soquelitinib in patients with moderate to severe eczema. On Friday alone, the stock jumped to its highest price of $26.95 before giving up all gains to end the session down by ...

SOUTH SAN FRANCISCO, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the closing of an upsized underwritten public offering of 9,085,778 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 1,185,101 additional shares, at a price to the public of $22.15 per share. Gross proceeds from the underwritten public offering before deducting underwriting discounts and com ...

Investment Rating - The report does not explicitly state an investment rating for the industry or specific companies. Core Insights - The report highlights significant developments in the overseas pharmaceutical sector, including the collaboration between Insilico Medicine and Heng Tai Biopharma to develop a novel NLRP3 inhibitor for central nervous system diseases [2][6]. - The report notes that MicroPort Robotics expects a revenue growth of approximately 110%-120% year-on-year for 2025, with an adjusted net loss not exceeding 240 million yuan, representing a reduction of over 50% [5][6]. - GSK has reached a final agreement to acquire RAPT Therapeutics for approximately 2.2 billion USD, focusing on a long-acting monoclonal antibody currently in clinical trials [7][8]. Summary by Sections 1. Overseas Pharmaceuticals - Insilico Medicine and Heng Tai Biopharma have entered a partnership to develop ISM8969, a novel oral NLRP3 inhibitor, with both companies holding 50% global rights [2][6]. - The Hong Kong Stock Exchange has approved the full circulation of 182,645,856 H shares for Fuhong Hanlin, representing about 33.61% of the company's total issued shares as of January 19 [2][6]. - The new drug application for TLX591-CDx, a radiopharmaceutical for prostate cancer diagnosis, has been accepted by the NMPA [2][6]. 2. Company Updates - MicroPort Robotics has reported over 180 commercial orders and more than 120 installations globally as of January 21 [5][6]. - Legend Biotech, a joint venture of Genscript Biotech, reported a trade sales net of approximately 555 million USD for the quarter ending December 31, 2025 [5][6]. - GSK's acquisition of RAPT Therapeutics includes a payment of 58.00 USD per share, with an expected upfront investment of 1.9 billion USD after cash adjustments [7][8]. 3. Market Performance - The Hang Seng Healthcare Index fell by 4.35%, underperforming the Hang Seng Index by 3.26 percentage points [4]. - The report indicates a strong performance in the overseas education sector, with GMV for Dongfang Zhenxuan reaching approximately 310 million yuan, a 42.8% increase week-on-week [15][16]. 4. Recommendations - The report suggests focusing on innovative drugs and the ongoing clinical progress of key pipelines from companies such as BeiGene, Innovent Biologics, and others [12]. - It also recommends monitoring the performance of educational companies like Dongfang Zhenxuan and China Oriental Education, which are expected to benefit from improved operational strategies and increased enrollment [16].

Core Viewpoint - Corvus Pharmaceuticals, Inc. has announced an upsized underwritten public offering of 7,900,677 shares at a price of $22.15 per share, aiming to raise approximately $175.0 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The offering includes a 30-day option for underwriters to purchase an additional 1,185,101 shares at the public offering price [1]. - The expected closing date for the offering is around January 23, 2026, pending customary closing conditions [2]. Group 2: Use of Proceeds - The net proceeds from the offering are intended for working capital and general corporate purposes, which may encompass capital expenditures and research and development for various clinical trials, including Phase 3 T cell lymphoma and Phase 2 trials for atopic dermatitis, hidradenitis suppurativa, and asthma [2]. Group 3: Underwriters - Jefferies and Goldman Sachs & Co. LLC are serving as lead book-running managers for the offering, with Mizuho as the bookrunner and Ladenburg Thalmann & Co. Inc. as a co-manager [3]. Group 4: Company Overview - Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing ITK inhibition as a novel immunotherapy approach for various immune diseases and cancers. The lead product candidate is soquelitinib, currently in a Phase 3 trial for relapsed/refractory PTCL and a Phase 1 trial for atopic dermatitis [6].

Investors with a lot of money to spend have taken a bearish stance on Corvus Pharma (NASDAQ:CRVS).And retail traders should know.We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CRVS, it often means somebody knows something is about to happen.Today, Benzinga's options scanner spotted 14 options trades for Corvus Pharma.This ...

Corvus Pharmaceuticals, Inc. ( CRVS ) lead asset would have to be soquelitinib. It's an investigational oral small-molecule drug being developed by Corvus. It's been seen to selectively inhibit interleukin-2–inducibleI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciation fo ...

Barclays maintains an "Overweight" rating for CRVS, raising its price target from $16 to $28.CRVS announced a $150 million public offering to fund working capital and corporate purposes.Positive Phase 1 trial data for soquelitinib shows strong efficacy and safety, doubling CRVS stock price.Corvus Pharmaceuticals (NASDAQ: CRVS) is a clinical-stage biopharmaceutical company based in South San Francisco, focusing on developing innovative therapies for immune-related diseases. Recently, Barclays maintained an " ...

Corvus Pharmaceuticals (NASDAQ:CRVS), an immuno-oncology and dermatology drug developer, closed Tuesday at $21.41, up 165.96%. The stock moved higher after Phase 1 soquelitinib data in atopic dermatitis (eczema) showed strong efficacy and clean safety, and investors are watching further development of the eczema program.Trading volume reached 82 million shares, about 3,032% above its three-month average of 2.6 million shares. Corvus Pharmaceuticals IPO'd in 2016 and has dropped 44% since going public. How ...